ADDITION OF LEADING SUPPLIERS BOLSTERS PRECISION’S BIOMARKER SERVICE OFFERINGS– BRINGING UNPARALLELED SCIENCE, SCALE, AND SERVICE TO THE BIOSPECIMEN INDUSTRY
BETHESDA, MD – August 1, 2019 – Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale.
The addition of ProMedDx and GLAS establishes an unrivaled biospecimen solutions platform within Precision, which operates one of the largest biorepositories in the world. ProMedDx is known throughout the diagnostics industry for its high-quality biofluid specimens, while GLAS is a leader in tissue-based samples. With an expanded sourcing network and client base, along with an enhanced global laboratory infrastructure, Precision can effectively leverage its unique insight as a scientific solutions provider to supply clients with hand-selected, fit-for-purposes specimens for R&D, biomarker development, and companion diagnostics.
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Combining two world-class biospecimen organizations, across all specimen types, Precision further enhances its abilities to enable life science innovators with scientifically robust services to accelerate the pace of discovery, development, and commercialization of biomarkers.
ProMedDx is led by founders Jim Boushell and Jim Sperzel; GLAS is led by founder and pathologist Cullen Taylor, MD.
Commenting on the significance of the acquisitions, Precision for Medicine president Chad Clark explains, “We believe in the power of biomarkers to lead to novel, life-changing therapies, and we remain dedicated to providing unmatched, scientifically grounded global services. By bringing ProMedDx and GLAS into the Precision family, we are proud to offer unparalleled, global biospecimens solutions while also expanding our footprint in the exploding Massachusetts and North Carolina biotechnology sectors.”
In describing Precision’s unique capabilities, ProMedDx co-founder Jim Boushell comments, “Precision’s reputation as an expert in biomarker sciences is a real differentiator. Having been in the specimen industry for over 20 years, I can attest there are no other companies that possess Precision’s level of scientific understanding or breadth of solutions. We are thrilled to be joining Precision and leveraging its translational and scientific expertise to deliver the highest-quality solutions to the biopharmaceutical and diagnostic industry.”
Cullen Taylor, MD of GLAS adds, ”Clearly, the life sciences industry relies heavily upon medical and scientific insight. However, this expertise is often in short supply in biospecimen provision. It’s why we founded GLAS. By teaming up with Precision, we are able to expand this on-the-ground medical expertise to a highly advanced and expansive lab and clinical network—a hugely important distinction in the biospecimen industry.”
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with nearly 2,000 employees in 34 locations in the US, Canada, and Europe. For more information, visit precisionformedicine.com. For more information about our biospecimen solutions, visit precisionbiospecimens.com.
# # #
Media Contact:
Louis Landon, Precision Medicine Group Media Relations
310-984-7707
louis.landon@precisionmedicinegrp.com
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.
Senior Vice President, In Vitro Diagnostics and Quality
Leader and innovator in the GMP/ISO/FDA/EU-regulated in vitro diagnostic (IVD) industry. Spearheads regulatory approvals worldwide for both novel and traditional IVD assays and products, as well as laboratory developed tests in the United States. Builds ground-up quality systems, meeting the requirements of US FDA, ISO 13485, CLIA, and CAP.
Vice President, Clinical Solutions, Project and Clinical Trial Management
Extensive experience in leading international Clinical Trial project teams across Europe and APAC in pharmaceutical industry and CRO environment. Reliable and flexible leader in managing execution of global clinical trials.
Senior Director, In Vitro Diagnostics and Quality
Scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms.
Senior Director, Global Program Management Translational & Lab Services
Industry veteran with deep expertise in large phase 3, open label and post marketing trials. Adept at managing potential execution and delivery constraints, working across teams globally to ensure that projects remain within the established timelines and budgets.
Vice President, General Manager UK Labs
Experienced leader of scientific operations for drug discovery in both the pharmaceutical and CRO industries. Driven to provide actionable data enabling biopharmaceutical research and development. Collaborative partner ensuring licensing and scientific support for corporate development initiatives.
Senior Director, Translational Business Solutions, Europe & APAC
Passionate leader combining a scientific background in immunology with significant business development experience. Expert at supporting pre-clinical research and biomarker data analysis. Committed to balancing science, team coordination, and communication to achieve excellence in project delivery and accelerate oncology drug development programs.
Senior Director, Clinical Business Solutions
Seasoned business development expert dedicated to working creatively within sponsors’ operational and financial parameters to bring new oncology and rare disease treatments to patients. Track record in establishing productive long-term relationships. Managed international oncology clinical operations teams, sales and marketing, and laboratory research.
Senior Vice President, Global Operational Strategy
Veteran of global oncology clinical operations, with in-depth experience in phase 1-3 oncology and hematology research as well as early-phase studies. Builder of world-class oncology research teams and leader of strategic growth of resources and operations across Europe. Keenly focused on study delivery, mitigation of study risk, and client service.
Senior Vice President, QuartzBio
Experienced strategist specializing in the development of technology-enabled solutions for the life science industry. Authority in maximizing the value of complex biomarker data and increasing the efficiency of research & development operations. Expertise with rapidly scaling technology-enabled businesses.
Sr. Director, Cell & Gene Therapy Analytical CDx Services
Respected scientist and bioanalytical leader focused on clinical development of companion diagnostics for rare diseases and oncology. American board-certified medical laboratory immunologist. Holds a CLIA high complexity/New York State lab director’s qualification in Diagnostic Immunology and Clinical Chemistry.
Vice-President, Medical
Strategic, innovation-driven, drug discovery veteran—and board-certified oncologist—with extensive international (EMA and FDA) regulatory experience. Record of excellence in clinical development, medical monitoring and medical strategy, and managing and mentoring cross-functional and global teams for phase 1-4 onco-hematology studies.
Senior Director of Clinical Business Solutions, EU & APAC
Leading authority in clinical CROs, focused on client services and regional growth implementation. Dedicated proponent of harnessing truly personalized medicine to develop more effective treatments for patients. Brings that passion to client support.
Medical Director, Clinical Operations
Leading physician with deep experience in clinical operations and medical monitoring management for phase 1-3 studies across indications, including onco-hematological, rare, cardiological, dermatological, and pulmonological disease trials. Noted medical strategist with excellent understanding of the complete drug development process.
Executive Vice President, Clinical Solutions
Veteran strategist and industry leader, with experience spanning all aspects of global clinical development for biotech, CRO and biopharma clinical research. Expert in end-to-end drug development operations, from early development through product approval.
Vice President, Immunology
Trusted global leader in immune-oncology and infectious disease research. Deep expertise in flow cytometry assay development, cell-based assays and biomarker discovery, clinical sample testing, and validation for early and late phase clinical trials. Client-facing strategist for translational studies.
Vice President, Computational Biology, QuartzBio
Leading authority on developing and applying computational approaches for multiomic biomarker discovery to aid precision medicine development from discovery through the clinic. Strong focus on high definition modeling of the mechanistic underpinnings of drugs and disease through deep biological knowledge. Specialized expertise integrating patient generated health data with molecular biomarkers.
Vice President, Bioanalytical Services
Dynamic and diverse experience leading scientific, operational, marketing, and sales efforts for drug development programs. Specialist in the development and oversight of ligand binding and cell-based assays supporting immunogenicity, phamacokinetics, pharmacodynamic biomarkers and neutralizing antibody assessments.
Senior Director, Business Development
Biotechnology industry veteran with dual emphasis on research and business and a focus on translational sciences. Expertise spans biomarkers, oncology and rare disease, diagnostics, and translational medicine. Holds a Master’s in Veterinary Microbiology from the University of Saskatchewan, and an MBA from San Jose State University.
Senior Director, Biomarker Data Management Systems & Data Integration
Expert in multi-modal data management and analysis, with an extensive background in clinical NGS data. Deep experience developing methods across wide range of commercial, service, and operational verticals in biotech and clinical settings. Holds a doctorate in Biophysics from The Scripps Research Institute.
Senior Director, Clinical Business Solutions
Respected business development strategist, building successful clinical programs for clients in Massachusetts. Innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Experienced in executing phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management.
Senior Director, Business Development
Healthcare industry veteran serving as the primary business development contact for life sciences clients in New England. Strategist focused on biomarker laboratory solutions for clinical trials across diverse indications. Holds a Master’s in Business Administration from Babson College and a Master of Science from Boston University.
Senior Vice President, Medical
Noted authority in the drug development industry. Sought-after strategist providing guidance for and oversight of the design, conduct, and analysis of oncology trials, and hands-on leadership for Precision’s team of oncology medical monitors. Expertise honed in clinical trials from phase 1-3 for a wide variety of anticancer drug classes and cancer types.
Senior Vice President, Clinical Operations
Respected leader managing the execution and delivery of all oncology clinical trials to ensure the highest quality service.
Chief Medical Officer, Clinical Solutions
Oncologist, hematologist and veteran expert in clinical research, clinical practice and development of pharmaceuticals, biologic products and immune modulation therapies. Primary consultant to the Moonshot 2020 program and an authority in optimizing clinical trial designs to accelerate product approval. Significant experience and credibility with the FDA as well as regulatory authorities in Europe, Japan and other countries.
Global Head of Strategic Development, Clinical Solutions
Notable authority in global operations, dedicated to fostering team spirit of excellence and collaboration with internal and external partners. Veteran of the quest to improve oncology therapies and extend lives, including 15+ years in oncology drug development, building on 10 years in obstetrics and women’s health.
Senior Vice President, Project Management and Clinical Operations Rare and Orphan Solutions
Global business strategist with more than 20 years of project and clinical management experience in the biopharma and CRO industries, spanning the full scope of studies. In-depth expertise in many therapeutic areas, including pediatric oncology, pediatric chronic pain, cancer pain, oncology, cardiovascular, CNS, biomarkers, infectious disease, gastroenterology, ophthalmology, Cystic Fibrosis, pediatric auto-inflammatory disorders, genetic sampling and medical device. Passionate about exploring ways to lessen the patient burden.
Senior Vice President, European Solutions
Industry leader in managing large global clinical trials. Co-founder of Argint International, a CRO providing clinical research and regulatory services to the pharmaceutical industry throughout central and south eastern Europe. Holds a masters in biology from Johannes Gutenberg-University in Mainz, Germany.
Senior Director, Europe Lead Biological
Leading expert in flow cytometry and systems biology and senior bioinformatics scientist. Core focus on exploratory immunological biomarker data analyses. Long-standing experience in the pharmaceutical industry. Holds a doctorate in cell biology from Friedrich Miescher Institute in Basel, Switzerland.
Senior Vice President, Business Operations Rare and Orphan Solutions
Accomplished and versatile leader with clinical development and R&D experience gained from academia, biopharma, and several top CROs. Unique skills developed as a laboratory researcher at the UCSD School of Medicine, in quality control in the biotech industry, in clinical operations, and as a senior executive. Dedicated to helping innovative companies bring new therapies to patients and families in greatest need.
Senior Director, Translational Biology & Biomarker Development
Authority in utilizing human primary biological tissue and cells in research and drug discovery. Developer of translational biomarkers for Phase I/II clinical programs in autoimmunity, inflammation and cancer. Expert in phenotypic cell-based assays using multiple primary cell systems such as T/Th17/T-regs, NK-T, B/Plasma/Plasmablasts, Myeloid cells, Dendritic cells (pDCc/mDCs), and MDSCs. Strategist in multi-parametric single-cell flow cytometry and analysis of flow cytometry data. Broad network of contacts at clinical sites and research hospitals, experienced with IRB submissions and clinical protocols. Scientific leader for Precision’s Biomaterials commercial sourcing.
President
Recognized industry leader focused on combining cutting-edge technology, strategic program design, and operational excellence to help life sciences companies effectively address the increasing evidence demands and need to accelerate research initiatives. Previous experience spans the execution of phase I-IV clinical trials, specialty lab services, biospecimen logistics and banking, risk management, and patient support initiatives.
Medical Director, Biospecimen Solutions
Visionary dedicated to enabling collaborations that help facilitate efficient translational research, discovery and development. Full-time pathologist and founder of the uniquely consultative biospecimens company Glas. Believes that forward-thinking pathologists and laboratorians should play a critical role in realizing the promise of translational medicine.
Senior Vice President
Visionary leader with more than 25 years of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases.
Senior Vice President, Diagnostics Solutions
Strategic visionary and healthcare industry veteran operating at the intersection of reimbursement, health economics, clinical science, and marketing strategy. Expertise encompasses all aspects of market access, reimbursement, and evidence development strategy, with a particular focus on personalized medicine, advanced molecular and companion diagnostics, and targeted therapies. Has launched successful products, guided major investment and acquisition decisions, and driven favorable coverage and payment determinations by public and private payers alike. Speaker and author.
Senior Vice President, Research Services
Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.
Senior Vice President, Biometrics Rare and Orphan Solutions
Seasoned veteran of the pharmaceutical and biotech industries both through CROs and sponsor companies. Provides statistical, technical, and strategic expertise for preclinical studies, INDs, Phase I-IV clinical studies, eCTDs, and postmarketing studies. Statistical expertise includes study design, protocol review, and writing and reviewing analysis plans and statistical reports. Skilled at representing clients at meetings with regulatory authorities, and as a statistical consultant for programs at all phases of development.
Senior Advisor, Rare Disease Solutions
Industry leader and founder of Agility Clinical, passionate about helping underserved patient populations. Keenly focused on orphan drug development with extensive experience in biostatistics, data management, and clinical operations. Accomplished executive leader with numerous awards, including, “Most Admired CEO”, “100 Most Inspiring People in the Pharmaceutical Industry”, “Athena Pinnacle Award for Women in Science and Technology”, and Ernst & Young “Entrepreneur of the Year” Finalist. Prior positions include founder and CEO of Synteract, a full-service, international contract research organization serving biopharma companies.
Senior Vice President, Operations & Customer Solutions
Extensive industry expertise across the pharmaceutical and biotech space-translational research, data management, and statistical support-with a focus in precision medicine-guided efforts in drug and diagnostic development. Subject matter expert in genomics. Pioneered approaches in biomarker data management and has led Biometrics operations on over 70 clinical studies.
Senior Vice President, Business Development
Clinical research veteran with a focus on strategic initiatives in the laboratory and biospecimen arena. Dedicated to helping pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products.
Scientific Liaison
Respected scientist and research investigator with expertise spanning biotechnology, medical science, technology development, and data analysis. Partners cross-functionally to identify and advance projects related to validation studies, method development, and reference standards.
Vice President, Biospecimen Solutions
Pioneer in the field of biospecimen procurement and co-founder of ProMedDx. Leader in the delivery of services for organizations in the biotechnology industry, including clinical study support and biostorage. Experienced executive with a demonstrated career of building innovative patient-centric biotech clinical programs. Focused on addressing the growing need for highly annotated, regulatory-compliant human biospecimens by the life science research communities.
Vice President, Biospecimen Solutions
Long-standing leader in the life sciences and in-vitro diagnostics industries. Co-founder of ProMedDx, a full suite of biospecimen solutions connecting biopharma teams to 1000s of clearly stratified and annotated cohorts. Expertise spanning operations, finance, human resources, government grant applications, and corporate strategy.
Senior Vice President, Laboratory Operations
Experienced senior leader spanning the academic, pharmaceutical, and CRO industries. Specific expertise in biotherapeutics and vaccines for preclinical and clinical development programs and in identifying the appropriate immunochemistry assays for new development programs. Broad record of accomplishment leading global teams, delivering business strategies, developing business, and ensuring operational excellence.
Chief Operating Officer, Oncology Solutions
Expert strategist for the pharmaceutical, CRO, and healthcare industries. Offers extensive multi-disciplinary drug development experience at the project, compound, and portfolio levels. Takes a sophisticated approach to the operations, infrastructure, and growth of Precision’s oncology division.
Senior Director, Europe Lead Informatics
Respected expert in mathematics and fundamental and theoretical computer science. Strong focus on genetics. Developer of innovative bioinformatics algorithms for SNP analyses and genome-wide association studies. Avid proponent of and proactive contributor to the open source community.
Senior Director, Europe Lead Operations
Distinguished expert in the analysis of large-scale, high-throughput genomics and genetics data. Statistical programmer combining computational and experimental methods in various therapeutic areas, including oncology and autoimmune disease.
Senior Director, Business Development
Influential strategy expert in end-to-end bioinformatics and artificial intelligence solutions for biomarker-guided drug development, maximizing the value and utility of biomarker data in clinical trials, CDx, and diagnostics. Previously CEO of SimplicityBio. Holds a doctorate in molecular and cellular biology from the University of Lausanne.
President, Clinical Solutions
Widely respected industry leader and founder of ACT Oncology. Guides strategic protocol design and study optimization on behalf of sponsors. Has extensive experience in Phase I-IV trials for most indications, including solid tumor and hematologic malignancies. Leads integrated teams to combine the strength of biomarker insights with clinical outcome data to optimize the development pathway.
Senior Director, Business Development, Oncology Solutions
30+ year healthcare industry veteran bridging business development efforts and program implementation for optimal client satisfaction. Serves as the primary business development contact for biotech and pharmaceutical clients on the west coast.
Senior Director, Client Solutions
Industry leader with deep expertise in healthcare technology focused on using artificial intelligence to help biopharma and diagnostic companies solve the question, “Which therapy, when, and for which patient?” Extensive industry knowledge across the pharmaceutical and biotech space—translational informatics, biomarker R&D. Holds an MBA and is passionate about exploring interfaces between people and technology for effective communication.
General Manager, Biospecimen Solutions
Respected vetran of the biospecimen and biomarker laboratory services industry. Honed his expertise through leadership roles in organizations including Roche, Cancer Genetics, and BioServe. Holds a Master of Public Health and a Masters of Business Administration from the Johns Hopkins University.
Senior Vice President, Business Operations
Vetran with deep knowledge of the contract research/pharmaceutical services industry. Provides project leadership and executive support to clients. Directs operational functions, resourcing, and business strategy internally, structuring oncology operations to match client needs.
Executive Director, Business Operations
Long-standing international CRO authority in the oncology drug development industry. Expertise spanning commercial operations, oncology and clinical operations, partnership development, and investigator networking.
Senior Director, Business Development
Research professional in both academia and industry, focused on bringing immune monitoring services to autoimmunity and tumor-immunology clinical trials. Specialist in innate and adaptive immunity, immunoassay development, onco-immunology, autoimmunity, target validation and preclinical biomarker discovery, and workflow and SOP design.
Managing Director, Translational Informatics and Diagnostic Sciences
Industry expert, leading regulatory submissions, translational informatics, and biomarker R&D for pharmaceutical and biotechnology companies. Focus on precision medicine-guided efforts, strategy, and medical device/diagnostic development. Global responsibility for translational informatics R&D efforts. Has led the development of novel methodologies for patient stratification and biomarker guided clinical trial design.
Director, Neurology Solutions
Trusted leader driving multi-site research programs that leverage proprietary state-of-the-art technologies to identify, validate, and integrate next-generation biomarkers to advance clinical trials for a wide range of neurological indications. Able to generate novel hypotheses, then identify and develop the right methods to answer the right scientific questions.
Senior Vice President, European Solutions
Industry leader with expertise managing large multinational clinical trials in 20+ countries across Europe, North America and APAC. Dedicated to providing quality, flexible and cost-effective solutions for clinical development programs.Co-founder of Argint International, a full-service CRO for phase I-IV clinical research trials. Holds a degree in microbiology from University of Warwick, United Kingdom.
Senior Vice President, Research
Inventor, industry expert, founder and leader of Epiontis. Developed the patents forming the basis of Epiontis’s intellectual property. Conducted pre- and postdoctoral research at the Center for Molecular Biology and Biomedicine (ZMBH) of the University of Heidelberg, Germany, and the R.W. Johnson Pharmaceutical Research Institute, San Diego, California, USA. Received a BSc from the Imperial College of Science, Technology, and Medicine, London, and a PhD in Biochemistry from the University of London.
Vice President, Oncology Solutions Site Network
Industry vetran and leader of Precision Oncology Site Network. Clear focus on consistently optimizing start-up at both academic and community-based sites across the United States and Europe. Oversaw the world’s largest phase 1 program for cancer research and treatment at the renowned University of Texas MD Anderson Cancer Center.
Senior Vice President, Product Development & Systems Integration
Distinguished expert working across the pharmaceutical and biotech space, leading regulatory submissions, translational informatics, and biomarker R&D. Clear focus on precision medicine-guided efforts, strategy, and medical device/diagnostic development. Led numerous analytical R&D efforts and developed novel methodologies to harmonize and analyze data from high-throughput assays, translating it to value at the patient level.
Vice President Immune Monitoring Solutions
Veteran biochemist, industry expert, cofounder of Epiontis. Holds a Master’s in Biochemistry from Humboldt University, a PhD from the Charité University Clinic receiving the Charité Research Award, and an MBA from the Berlin School of Economics and Law, Berlin, Germany.
